Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP)
- 8 August 2018
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 10 (453)
Abstract
A drug discovery and optimization platform uncovered effective therapeutic combinations for bortezomib-resistant multiple myeloma.Keywords
Funding Information
- National Science Foundation (CMMI-1350197)
- National Science Foundation (DMI-0327077)
- National Science Foundation (CMMI-0856492)
- National Science Foundation (DMR-1343991)
- National Cancer Institute (U54CA151880)
- Ministry of Education - Singapore (MOE2015-T2-2-126)
- Ministry of Education - Singapore (MOE2014-T3-1-006)
- Ministry of Education - Singapore (T1-2012 Oct -04)
- National Medical Research Council (BNIG11nov001)
This publication has 59 references indexed in Scilit:
- Interpreting cancer genomes using systematic host network perturbations by tumour virus proteinsNature, 2012
- Risk estimation and risk prediction using machine-learning methodsHuman Genetics, 2012
- Negative Feedback and Adaptive Resistance to the Targeted Therapy of CancerCancer Discovery, 2012
- Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapyGenes & Development, 2012
- Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000–05): an open-label, randomised, phase 3 trialThe Lancet Oncology, 2011
- Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer ModelingScience Translational Medicine, 2011
- Identification of Optimal Drug Combinations Targeting Cellular Networks: Integrating Phospho-Proteomics and Computational Network AnalysisCancer Research, 2010
- Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastomaProceedings of the National Academy of Sciences, 2007
- Drug repositioning: identifying and developing new uses for existing drugsNature Reviews Drug Discovery, 2004
- Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myelomaBlood, 2002